AnaptysBio Inc ANAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ANAB is a good fit for your portfolio.
News
-
Actym Therapeutics Appoints Thomas Smart as CEO
-
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
-
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
-
Anaptys Sees Positive Trial Results for Imsidolimad Psoriasis Treatment
-
AnaptysBio Shares Rise 11% After Jemperli Plus Chemotherapy Approved in U.S.
Trading Information
- Previous Close Price
- $18.83
- Day Range
- $18.83–19.29
- 52-Week Range
- $13.37–27.32
- Bid/Ask
- $19.08 / $19.42
- Market Cap
- $526.98 Mil
- Volume/Avg
- 6,598 / 330,424
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 30.24
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 9.41%
Company Profile
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 117
- Website
- https://www.anaptysbio.com
Comparables
Valuation
|
Metric
|
ANAB
|
CLDX
|
ALLK
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.82 | 4.82 | 0.55 |
Price/Sales | 30.24 | 260.58 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ANAB
CLDX
ALLK
Financial Strength
|
Metric
|
ANAB
|
CLDX
|
ALLK
|
|---|---|---|---|
Quick Ratio | 10.62 | 13.69 | 8.27 |
Current Ratio | 10.87 | 13.87 | 9.31 |
Interest Coverage | −9.09 | — | — |
Quick Ratio
ANAB
CLDX
ALLK
Profitability
|
Metric
|
ANAB
|
CLDX
|
ALLK
|
|---|---|---|---|
Return on Assets (Normalized) | −23.50% | −30.49% | −45.63% |
Return on Equity (Normalized) | −75.96% | −33.19% | −58.46% |
Return on Invested Capital (Normalized) | −68.56% | −32.85% | −53.25% |
Return on Assets
ANAB
CLDX
ALLK
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ntvtnpqvk | Hzsr | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kpskgpx | Rnnzsh | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zbyyysnk | Xljzcy | $97.8 Bil | |
MRNA
| Moderna Inc | Tyqyzdxb | Xjqn | $38.8 Bil | |
ARGX
| argenx SE ADR | Qmmqhvrf | Gdl | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Mhcmdytg | Hrxlh | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zbfkxvjk | Ssbwgt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yqqwjvg | Bswvfx | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gcgclgsdxf | Fwgkrf | $12.5 Bil | |
INCY
| Incyte Corp | Ghpddphm | Qtyhczj | $11.5 Bil |